文献速递免疫规划妇幼与学校卫生

乌干达儿童中单价轮状病毒疫苗对需住院治疗的轮状病毒胃肠炎的有效性

Effectiveness of monovalent rotavirus vaccine against hospital-attended rotavirus gastroenteritis among children in Uganda.
PubMed 文献 · Vaccine · 2025-01-14

在乌干达3家医院比较187例轮状病毒腹泻病例与622例非轮状病毒腹泻对照的疫苗接种状态,调整年龄、出生年月和医院后,4-59月龄儿童全程2剂疫苗有效性为29%(95%CI:-37%-63%),4-11月龄婴儿为62%(9%-84%),12-59月龄儿童为-69%(-401%-43%),对部分异型株有效性为59%(1%-83%)。

要点

  • 4-59月龄儿童全程2剂Rotarix对轮状病毒腹泻住院的有效性为29%(95%CI:-37%-63%)。
  • 4-11月龄婴儿2剂有效性为62%(95%CI:9%-84%),12-59月龄儿童为-69%(95%CI:-401%-43%),组间P=0.20。
  • 对部分异型轮状病毒株(包括最常见流行基因型G3P[8])的有效性为59%(95%CI:1%-83%)。

核心结论

  • 常规Rotarix接种可有效预防乌干达婴儿因轮状病毒腹泻住院,但保护未持续至1岁以后。
  • 对部分异型轮状病毒株显示出保护作用。
  • 这些结果支持在乌干达继续使用轮状病毒疫苗。
  • 需要额外研究以理解乌干达及其他高儿童死亡率地区轮状病毒疫苗有效性较低的原因。

研究设计与样本

  • 比较年龄符合接种Rotarix的实验室确诊轮状病毒腹泻病例与非轮状病毒腹泻对照的疫苗接种状态。
  • 研究对象为2018年10月至2022年12月入住乌干达3家医院的儿童。
  • 共纳入187例病例和622例对照。
  • 使用非条件logistic回归计算疫苗有效性,调整年龄、出生年月和医院。

主要发现

  • 病例组93%(173/187)和对照组93%(579/622)接种过至少1剂Rotarix。
  • 4-59月龄儿童全程2剂疫苗调整有效性为29%(95%CI:-37%-63%)。
  • 4-11月龄婴儿2剂有效性为62%(95%CI:9%-84%),12-59月龄儿童为-69%(95%CI:-401%-43%),两组比较P=0.20。
  • 对部分异型株(包括最常见流行基因型G3P[8])的有效性为59%(95%CI:1%-83%)。

临床怎么用

  • 作者结论认为这些结果支持在乌干达继续使用轮状病毒疫苗。
  • 作者指出需要额外研究以理解乌干达及其他高儿童死亡率地区轮状病毒疫苗有效性较低的原因。

局限性

  • 作者指出需要额外研究以理解乌干达及其他高儿童死亡率地区轮状病毒疫苗有效性较低的原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The underlying causes for lower rotavirus vaccine effectiveness (VE) in high-child-mortality settings are not well understood. Uganda introduced the human monovalent G1P[8] rotavirus vaccine (Rotarix) in June 2018. We determined the effectiveness of Rotarix against rotavirus diarrhea requiring hospital care among Ugandan children. METHODS: We compared the vaccination status of children with laboratory-confirmed rotavirus (cases) and non-rotavirus (controls) diarrhea who were age-eligible to receive Rotarix and admitted to 3 hospitals in Uganda October 2018-December 2022. VE ([1-odds ratio of vaccination among cases and controls] x 100]) was calculated using unconditional logistic regression adjusting for age, birth month-year, and hospital. RESULTS: Among 187 cases and 622 controls, respectively, 93 % (173/187) and 93 % (579/622) had received ≥1 doses of Rotarix. Adjusted full-series (2 dose) VE against rotavirus diarrhea was 29 % (95 % confidence interval: -37 %-63 %) in children 4-59 months of age. Two-dose VE was 62 % (9 %-84 %) in infants 4-11 months of age and - 69 % (-401 %-43 %) in children 12-59 months of age (P = 0.20). VE against strains partially-heterotypic to the vaccine strain (including G3P[8], the most common curculating genotype) was 59 % (1 %-83 %). CONCLUSIONS: Routine Rotarix vaccination was effective in preventing hospital visits for rotavirus diarrhea among Ugandan infants, although protection was not sustained after the first year of life. Protection was demonstrated against partially heterotypic rotavirus strains. These results support the continued use of rotavirus vaccines in Uganda. Additional studies are needed to understand the lower rotavirus VE seen in Uganda and other high-mortality settings.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Aanyu HT, Nalunkuma C, Kaudha E, et al. Effectiveness of monovalent rotavirus vaccine against hospital-attended rotavirus gastroenteritis among children in Uganda. Vaccine. 2025. PMID: 39813975. doi:10.1016/j.vaccine.2025.126726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。